论文部分内容阅读
本文对103例膀胱肿瘤和121例泌尿系非肿瘤病人膀胱冲洗液进行了290次流式细胞分析(FCM)检测,前者FCM阳性者94例,FCM阳性率为91.3％;后者FCM阳性者6例,FCM假阳性率为5％。上述103例膀胱肿瘤病人在治疗前均做过尿细胞学检查和膀胱镜检查,尿细胞学检查阳性者42例,阳性率40.8％,膀胱镜检查发现肿瘤者96例,不能作出诊断者7例,其中6例FCM检测阳性。结果提示,FCM存诊断膀胱肿瘤方面明显优于尿细胞学检查,并在一定程度上,可与膀胱镜检查相互弥补存诊断膀胱肿瘤方面存在的不足。
In this study, flow cytometry (FCM) was performed on 103 bladder cancer patients and 121 non-tumor urinary bladder patients. Of the 94 patients, 94 were FCM positive and the positive rate of FCM was 91.3% For example, the false positive rate of FCM is 5%. The 103 cases of bladder cancer patients before treatment were done urine cytology and cystoscopy, urine cytology positive in 42 cases, the positive rate of 40.8%, cystoscopy found that the tumor in 96 cases, can not make a diagnosis of 7 cases , Of which 6 cases of positive FCM test. The results suggest that FCM is superior to urinary cytology in the diagnosis of bladder cancer, and to a certain extent, can complement with cystoscopy to make up for the shortcomings in the diagnosis of bladder cancer.